Keith A. Goldan insider trades

Open-market stock purchases and sales by Keith A. Goldan, Chief Financial Officer at Syndax Pharmaceuticals Inc, from SEC Form 4 filings since Aug 11, 2010.

Track record: 0% of 1 scored buy are up 5% or more since purchase, averaging -15%.

Recent trades

DateStockTradeValue
Jun 1, 2026SNDX Syndax Pharmaceuticals IncSold$22.4K
Apr 1, 2026ABEO Abeona Therapeutics IncBought (not open market)—
Feb 9, 2026SNDX Syndax Pharmaceuticals IncSold$71.7K
Feb 6, 2026SNDX Syndax Pharmaceuticals IncSold$42.9K
Feb 4, 2026SNDX Syndax Pharmaceuticals IncBought (not open market)—
Feb 4, 2026SNDX Syndax Pharmaceuticals IncBought (not open market)—
Feb 4, 2026SNDX Syndax Pharmaceuticals IncBought (not open market)$2.4M
Jan 30, 2026SNDX Syndax Pharmaceuticals IncBought (not open market)$10.3K
Dec 1, 2025SNDX Syndax Pharmaceuticals IncSold (not open market)—

Companies traded

  • SNDX Syndax Pharmaceuticals Inc: 2 buys, 6 sales, last Jun 1, 2026
  • ABEO Abeona Therapeutics Inc: other filings, last Apr 1, 2026
  • OPTN OptiNose, Inc: 1 buy, 5 sales, last Mar 16, 2022
  • FCSC Fibrocell Science, Inc: 1 buy, last Mar 1, 2016
  • PATH Nupathe Inc: other filings, last Feb 21, 2014

Get free alerts when Keith A. Goldan files a new trade →